Vijay Mallya Quits as Chairman of Sanofi India

Subject to fulfilling all requirements, Narayan, 64, is slated to take over as the next SIL Chairman in place of Mallya.

Published: 24th March 2016 10:41 AM  |   Last Updated: 24th March 2016 12:06 PM   |  A+A-

Vijay Mallya AFP

Chairman and CEO of India's Kingfisher Airlines Vijay Mallya talks on his cellphone during a meeting with pilots in New Delhi on March 15, 2012. (File | AFP)


MUMBAI: Beleaguered business tycoon Vijay Mallya has decided to step down as the chairman of pharma major Sanofi India, nearly 33 years after he assumed the post, the company said in a statement here.

Mallya conveyed his decision not to seek re-election as a director at the company's ensuing Annual General Meeting, said the Sanofi statement issued late Wednesday.

Mallya had first joined in December 1973 as director of Sanofi India Ltd (SIL), then known as Hoechst Pharmaceuticals Ltd. He functioned as the board chairman since December 1983.

"I have been privileged to preside over the board of this company, which started as Hoechst Pharmaceuticals Ltd. and to have participated in its phenomenal growth and prosperity over such an extraordinarily long period of time," Mallya said in a farewell statement.

"It was gratifying that the company continued serving needy patients in India with world-class medication while ensuring consistent returns to all stakeholders."

Mallya, who is believed to be hiding in the United Kingdom, is wanted by the Enforcement Directorate (ED) in connection with a money-laundering case. The former liquor baron -- known as 'king of good times' -- has denied that he was "absconding", saying as an "international businessman" he is currently abroad on a business trip and was expected to return by March-end.

SIL Managing Director Shailesh Ayyangar said under Mallya's leadership, in the past 10 years, the company's sales grew from Rs.800 crore to Rs.2,000 crore, share price shot up from Rs.1,655 to Rs.4,358, market cap has almost tripled and the employee strength more than doubled from 1,500 to 3,700.

The SIL announced plans to induct Aditya Narayan and Usha Thorat as two new independent directors for five years from April 30, 2016. Subject to fulfilling all requirements, Aditya Narayan, 64, is slated to succeed Mallya as SIL Chairman.

SIL is listed on both BSE and NSE. Its parent Sanofi has 60.4 percent equity stake in SIL whose portfolio includes pharmaceuticals and consumer healthcare products.

In pharma, SIL has a strong presence in diabetes, being the only company with a balanced oral and insulin portfolio.


Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on are those of the comment writers alone. They do not represent the views or opinions of or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp